音量 3, 問題 12 (2013)
総説
Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point
Paolo Spagnolo,Fabrizio Luppi
レビュー: 臨床試験の結果
Macrolide therapy in cystic fibrosis: new developments in clinical use
K Frayman,P Robinson
レビュー: 臨床試験の結果
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Roberto Lorenzetti, Cosimo Prantera
総説
Surrogate end points: when should they be used?
Geert Molenberghs, Ariel Alonso Abad, Wim van der Elst, Tomasz Burzykowski, Marc Buyse
研究の最新情報
Developing a consortium for ALS clinical research: the Canadian ALS Research Network
Lorne Zinman, Angela Genge,Denise A Figlewicz
レビュー: 臨床試験の結果
Neuroprotective agents in ischemic stroke: past failures and future opportunities
Jiangyong Min, Muhammad U Farooq, Philip B Gorelick
総説
Measuring symptoms as a critical component of drug development and evaluation in hematological diseases
Loretta A Williams, Emre Yucel, Jorge E Cortes,Charles S Cleeland
